

DRAFT AGENDA
Strategic Affairs Committee

January 23, 2019
10:15 am – 12:00 pm

1. Introductions and Agenda Review

2. Sub-Committee
 - By-Laws: Ken
 - Clarify member versus advisor participation on committees, task forces or work groups (OP, page 20)
 - AAFCO Conflict of Interest (COI) sign off for Chairs and Investigators
 - Consider examples of potential conflicts that are open but don't preclude other issues.
 - By-Laws investigate whether COI is needed where state/federal members have already signed COI with their respective employers. FDA will follow up where there are investigators that are FDA employees who have also signed COI.
 - By-Laws: clarify whether it is COI that prohibits versus disclosure for evaluation and more education/awareness of AAFCO members who will be asked to sign COI.

3. Strategic Planning 2017-20
 - Update from Responsible Committees
 - Addressing more priority goals

4. Strategic Planning 2021+

5. Vision/Mission Statement update: Stan

6. Other business

Action Item Table:

Responsible	Item	Action	Timing / Status
Linda/ Committee Chairs	Strategic Plan priorities 2017-20	Update FeedBin. Committee chairs asked to update as they make progress.	Update FeedBin per August 2018 Annual meeting reporting.
Board	Vision/mission statement review	Recommendation to the Board to consider holding a session to review and update the vision/mission statement as appropriate, with a facilitator experienced in this area. The Board met the same afternoon and supported holding a Board session at Seminar.	October 2018 Board session held to finalize. Complete
By-Laws (Ken)	OP, page 20 Committee advisors sentence	Review "Committee advisors do not serve as members of an AAFCO committee, task force or work group, nor do they have a vote in any AAFCO deliberations." to better clarify member versus advisor participation on committees, task forces or work groups.	January 2019
By-Laws (Ken)	AAFCO Conflict of Interest (COI) sign off for Chairs and Investigators	<ol style="list-style-type: none"> 1. Consider examples of potential conflicts that are open but don't preclude other issues. 2. By-Laws investigate whether COI is needed where state/federal members have already signed COI with their respective employers. FDA will follow up where there are investigators that are FDA employees who have also signed COI. 3. By-Laws: clarify whether it is COI that prohibits versus disclosure for evaluation and more education/awareness of AAFCO members who will be asked to sign COI. 	January 2019